Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619136 | 0.81 | HCAR2 (0.43) | HCAR2KCNH2HCAR3NPC1RAB9A | |
| SCHEMBL15334778 | 0.77 | — | — | |
| SCHEMBL10157463 | 0.77 | — | — | |
| SCHEMBL7217929 | 0.75 | — | — | |
| SCHEMBL17164752 | 0.73 | KCNH2 (0.37) | HCAR2KCNH2HCAR3HSD17B10HTT | |
| SCHEMBL8943452 | 0.73 | KCNH2 (0.37) | HCAR2KCNH2HCAR3HSD17B10P2RX7 | |
| SCHEMBL7320150 | 0.73 | — | — | |
| SCHEMBL5752138 | 0.73 | KCNH2 (0.37) | HCAR2KCNH2HCAR3HSD17B10P2RX7 | |
| SCHEMBL23869552 | 0.71 | HCAR2 (0.31) | HCAR2HSD17B10 | |
| Hydrochloric Acid SCHEMBL11445607 | 0.71 | GAA (0.41) | HCAR2NPC1RAB9AHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2855449-B1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20170340621-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-30 | — | — | US | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-05 | — | — | US | disclosed |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | disclosed |
| EP-0366329-B1 | Halogeno-4-methylpyrazoles and process for preparing the same | NISSAN CHEMICAL IND LTD (JP) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122317-A1 | 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS | GIPR, PROKR1, PROKR2 | HCAR2 374/4885KCNH2 762/4885HCAR3 207/4885 |
| US-20170340621-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS | PROKR1, PROKR2, GIPR | HCAR2 700/4885KCNH2 302/4885HCAR3 336/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HCAR2 4017/4885KCNH2 4619/4885HCAR3 4020/4885 |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PGC | HCAR2 1562/4885KCNH2 400/4885HCAR3 1182/4885 |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | HCAR2 3695/4885KCNH2 3117/4885HCAR3 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.